Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

In Vitro Drug Metabolism Using Liver Microsomes.

Knights KM, Stresser DM, Miners JO, Crespi CL.

Curr Protoc Pharmacol. 2016 Sep 16;74:7.8.1-7.8.24. doi: 10.1002/cpph.9.

PMID:
27636111
2.
3.

Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design.

Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N, Crespi CL, Stresser DM.

Xenobiotica. 2009 Feb;39(2):99-112. doi: 10.1080/00498250802638155.

PMID:
19255936
4.

Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine.

Stresser DM, Mason AK, Perloff ES, Ho T, Crespi CL, Dandeneau AA, Morgan L, Dehal SS.

Drug Metab Dispos. 2009 Apr;37(4):695-8. doi: 10.1124/dmd.108.025726. Epub 2009 Jan 14.

PMID:
19144769
5.

A novel design of artificial membrane for improving the PAMPA model.

Chen X, Murawski A, Patel K, Crespi CL, Balimane PV.

Pharm Res. 2008 Jul;25(7):1511-20. doi: 10.1007/s11095-007-9517-8. Epub 2008 Jan 10.

PMID:
18185985
6.
7.

Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation.

Chang TK, Crespi CL, Waxman DJ.

Methods Mol Biol. 2006;320:127-31.

PMID:
16719383
9.
10.

Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 2006;320:109-13.

PMID:
16719380
11.

High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 2006;320:103-7.

PMID:
16719379
12.
13.

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, Gan LS.

Mol Pharm. 2006 Jan-Feb;3(1):78-86.

PMID:
16686372
14.

Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54.

Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, Elaut G, Eletti B, Freidig A, Gennari A, Ghersi-Egea JF, Guillouzo A, Hartung T, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W, Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai E, Vericat JA, Worth A.

Altern Lab Anim. 2006 Feb;34(1):49-84. No abstract available.

PMID:
16522150
15.

Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.

Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J.

Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24.

PMID:
16501008
16.

High-Performance Liquid Chromatography Analysis of CYP2C8-Catalyzed Paclitaxel 6α-Hydroxylation.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 2006;320:103-107.

PMID:
27699666
17.

Human-cell mutagens in respirable airborne particles in the northeastern United States. 1. Mutagenicity of fractionated samples.

Pedersen DU, Durant JL, Penman BW, Crespi CL, Hemond HF, Lafleur AL, Cass GR.

Environ Sci Technol. 2004 Feb 1;38(3):682-9.

PMID:
14968851
18.

Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.

Stresser DM, Broudy MI, Ho T, Cargill CE, Blanchard AP, Sharma R, Dandeneau AA, Goodwin JJ, Turner SD, Erve JC, Patten CJ, Dehal SS, Crespi CL.

Drug Metab Dispos. 2004 Jan;32(1):105-12.

PMID:
14709627
19.

Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 1998;107:163-7. No abstract available.

PMID:
14577226
20.

Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation.

Chang TK, Crespi CL, Waxman DJ.

Methods Mol Biol. 1998;107:147-52. No abstract available.

PMID:
14577224
21.
22.

CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 1998;107:135-9. No abstract available.

PMID:
14577222
23.

Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 1998;107:129-33. No abstract available.

PMID:
14577221
24.

High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6 alpha-hydroxylation.

Crespi CL, Chang TK, Waxman DJ.

Methods Mol Biol. 1998;107:123-7. No abstract available.

PMID:
14577220
25.

Determination of the CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes.

Chang TK, Crespi CL, Waxman DJ.

Methods Mol Biol. 1998;107:117-22. No abstract available.

PMID:
14577219
26.

Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay.

Kragie L, Turner SD, Patten CJ, Crespi CL, Stresser DM.

Endocr Res. 2002 Aug;28(3):129-40.

PMID:
12489563
27.

CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes.

Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK.

Biochem Pharmacol. 2002 Dec 1;64(11):1579-89.

PMID:
12429347
28.

Design and application of fluorometric assays for human cytochrome P450 inhibition.

Crespi CL, Miller VP, Stresser DM.

Methods Enzymol. 2002;357:276-84. No abstract available.

PMID:
12424917
29.

Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4.

Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL.

Drug Metab Dispos. 2002 Jul;30(7):845-52.

PMID:
12065444
30.

Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man.

Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, Walker DK.

Xenobiotica. 2001 Aug-Sep;31(8-9):665-76.

PMID:
11569532
31.

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.

Chauret N, Dobbs B, Lackman RL, Bateman K, Nicoll-Griffith DA, Stresser DM, Ackermann JM, Turner SD, Miller VP, Crespi CL.

Drug Metab Dispos. 2001 Sep;29(9):1196-200.

PMID:
11502727
32.

Human cell mutagenicity of chlorinated and unchlorinated water and the disinfection byproduct 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX).

Woodruff NW, Durant JL, Donhoffner LL, Penman BW, Crespi CL.

Mutat Res. 2001 Aug 22;495(1-2):157-68.

PMID:
11448653
33.

Fluorometric screening for metabolism-based drug--drug interactions.

Crespi CL, Stresser DM.

J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):325-31.

PMID:
11274899
34.

Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression.

Crespi CL, Fox L, Stocker P, Hu M, Steimel DT.

Eur J Pharm Sci. 2000 Nov;12(1):63-8.

PMID:
11121734
35.
36.

Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL.

Drug Metab Dispos. 2000 Dec;28(12):1440-8.

PMID:
11095581
37.

Fluorometric high-throughput screening for inhibitors of cytochrome P450.

Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL.

Ann N Y Acad Sci. 2000;919:26-32.

PMID:
11083094
39.

A high-throughput screen to identify inhibitors of aromatase (CYP19).

Stresser DM, Turner SD, McNamara J, Stocker P, Miller VP, Crespi CL, Patten CJ.

Anal Biochem. 2000 Sep 10;284(2):427-30. No abstract available.

PMID:
10964434
40.

CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity.

Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ.

Clin Pharmacol Ther. 2000 Jan;67(1):48-56.

PMID:
10668853
41.

Differential protection by rat UDP-glucuronosyltransferase 1A7 against Benzo[a]pyrene-3,6-quinone- versus Benzo[a]pyrene-induced cytotoxic effects in human lymphoblastoid cells.

Grove AD, Llewellyn GC, Kessler FK, White KL Jr, Crespi CL, Ritter JK.

Toxicol Appl Pharmacol. 2000 Jan 1;162(1):34-43.

PMID:
10631125
42.

Mutagenicity of C24H14 PAH in human cells expressing CYP1A1.

Durant JL, Lafleur AL, Busby WF Jr, Donhoffner LL, Penman BW, Crespi CL.

Mutat Res. 1999 Oct 29;446(1):1-14.

PMID:
10613181
43.
44.

Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.

Hu M, Li Y, Davitt CM, Huang SM, Thummel K, Penman BW, Crespi CL.

Pharm Res. 1999 Sep;16(9):1352-9.

PMID:
10496649
45.

Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells.

Lanza DL, Code E, Crespi CL, Gonzalez FJ, Yost GS.

Drug Metab Dispos. 1999 Jul;27(7):798-803.

PMID:
10383923
47.

Assessing the potential for drug-drug interactions in an accelerated throughput mode.

Crespi CL.

Pharm Sci Technolo Today. 1999 Mar;2(3):119-120.

PMID:
10322365
48.
49.

Detection and characterization of novel polymorphisms in the CYP2E1 gene.

Fairbrother KS, Grove J, de Waziers I, Steimel DT, Day CP, Crespi CL, Daly AK.

Pharmacogenetics. 1998 Dec;8(6):543-52.

PMID:
9918138
50.

Higher-throughput screening with human cytochromes P450.

Crespi CL.

Curr Opin Drug Discov Devel. 1999 Jan;2(1):15-9.

PMID:
19649912

Supplemental Content

Loading ...
Support Center